Correlations between Her2 oncoprotein, VEGF expression, MVD and clinicopathological parameters in gastric cancer

Romanian Journal of Morphology and Embryology

Volumn 53, Issue 4, 2012, Pages 997-1005

  Bǎdescu, Alina ^a   Georgescu, Claudia Valentina ^a   Vere, C C ^a   Crǎiţoiu, Ştefania ^a   Grigore, Diana ^a  

^a UNIVERSITY OF MEDICINE AND PHARMACY OF CRAIOVA   (Romania)

Author keywords

Gastric carcinoma; Her2 neu; MVD; VEGF

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; BIOSYNTHESIS; ENZYMOLOGY; FEMALE; HUMAN; MALE; METABOLISM; MICROVASCULATURE; MIDDLE AGED; PATHOLOGY; STOMACH TUMOR; VASCULARIZATION; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; MALE; MICROVESSELS; MIDDLE AGED; RECEPTOR, ERBB-2; STOMACH NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84872239780     PISSN: 12200522     EISSN: 20668279     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Roder DM, The epidemiology of gastric cancer, Gastric Cancer, 2002, 5(Suppl 1):5-11.
2. De Vita F, Giuliani F, Galizia G, Belli C, Aurilio G, Santabarbara G, Ciardiello F, Catalano G, Orditura M, Neo-adjuvant and adjuvant chemotherapy of gastric cancer, Ann Oncol, 2007, 18(Suppl 6):vi120-vi123.
3. Orditura M, Martinelli E, Galizia G, Vitiello F, Fasano M, Muto P, Ciardiello F, De Vita F, Chemoradiotherapy as adjuvant treatment of gastric cancer, Ann Oncol, 2007, 18(Suppl 6):vi133-vi135.
4. Iwasaki J, Nihira S, Anti-angiogenic therapy against gastrointestinal tract cancers, Jpn J Clin Oncol, 2009, 39(9):543-551.
5. De Vita F, Giuliani F, Silvestris N, Catalano G, Ciardiello F, Orditura M, Human epidermal growth factor receptor 2 (HER2) in gastric cancer: a new therapeutic target, Cancer Treat Rev, 2010, 36(Suppl 3):S11-S15.
6. Fornaro L, Lucchesi M, Caparello C, Vasile E, Caponi S, Ginocchi L, Masi G, Falcone A, Anti-HER agents in gastric cancer: from bench to bedside, Nat Rev Gastroenterol Hepatol, 2011, 8(7):369-383.
7. Traxler P, Allegrini PR, Brandt R, Brueggen J, Cozens R, Fabbro D, Grosios K, Lane HA, McSheehy P, Mestan J, Meyer T, Tang C, Wartmann M, Wood J, Caravatti G, AEE788: a dual family epidermal growth factor receptor/ ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity, Cancer Res, 2004, 64(14):4931-4941.
8. Gravalos C, Jimeno A, HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target, Ann Oncol, 2008, 19(9):1523-1529.
9. Akiyama T, Sudo C, Ogawara H, Toyoshima K, Yamamoto T, The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity, Science, 1986, 232(4758):1644-1646.
10. Tapia C, Glatz K, Novotny H, Lugli A, Horcic M, Seemayer CA, Tornillo L, Terracciano L, Spichtin H, Mirlacher M, Simon R, Sauter G, Close association between HER-2 amplification and overexpression in human tumors of non-breast origin, Mod Pathol, 2007, 20(2):192-198.
11. Hofmann M, Stoss O, Shi D, Büttner R, van de Vijver M, Kim W, Ochiai A, Rüschoff J, Henkel T, Assessment of a HER2 scoring system for gastric cancer: results from a validation study, Histopathology, 2008, 52(7):797-805.
12. Jørgensen JT, Hersom M, HER2 as a prognostic marker in gastric cancer - a systematic analysis of data from the literature, J Cancer, 2012, 3:137-144.
13. Park DI, Yun JW, Park JH, Oh SJ, Kim HJ, Cho YK, Sohn CI, Jeon WK, Kim BI, Yoo CH, Son BH, Cho EY, Chae SW, Kim EJ, Sohn JH, Ryu SH, Sepulveda AR, HER-2/neu amplification is an independent prognostic factor in gastric cancer, Dig Dis Sci, 2006, 51(8):1371-1379.
14. Zhang XL, Yang YS, Xu DP, Qu JH, Guo MZ, Gong Y, Huang J, Comparative study on overexpression of HER2/neu and HER3 in gastric cancer, World J Surg, 2009, 33(10): 2112-2118.
15. Folkman J, Shing Y, Angiogenesis, J Biol Chem, 1992, 267(16):10931-10934.
16. Suzuki S, Dobashi Y, Hatakeyama Y, Tajiri R, Fujimura T, Heldin CH, Ooi A, Clinicopathological significance of platelet-derived growth factor (PDGF)-B and vascular endothelial growth factor-A expression, PDGF receptor-β phosphor-ylation, and microvessel density in gastric cancer, BMC Cancer, 2010, 10:659.
17. de la Taille A, Katz AE, Bagiella E, Buttyan R, Sharir S, Olsson CA, Burchardt T, Ennis RD, Rubin MA, Microvessel density as a predictor of PSA recurrence after radical prostatectomy. A comparison of CD34 and CD31, Am J Clin Pathol, 2000, 113(4):555-562.
18. Choi YH, Choi KC, Park YE, Relationship of transforming growth factor beta 1 to angiogenesis in gastric carcinoma, J Korean Med Sci, 1997, 12(5):427-432.
19. Zhao HC, Qin R, Chen XX, Sheng X, Wu JF, Wang DB, Chen GH, Microvessel density is a prognostic marker of human gastric cancer, World J Gastroenterol, 2006, 12(47): 7598-7603.
20. Ferrara N, Houck K, Jakeman L, Leung DW, Molecular and biological properties of the vascular endothelial growth factor family of proteins, Endocr Rev, 1992, 13(1):18-32.
21. Saito H, Tsujitani S, Ikeguchi M, Kaibara N, Relationship between the expression of vascular endothelial growth factor and the density of dendritic cells in gastric adenocarcinoma tissue, Br J Cancer, 1998, 78(12):1573-1577.
22. Hayashi M, Inokuchi M, Takagi Y, Yamada H, Kojima K, Kumagai J, Kawano T, Sugihara K, High expression of HER3 is associated with a decreased survival in gastric cancer, Clin Cancer Res, 2008, 14(23):7843-7849.
23. Yu GZ, Chen Y, Wang JJ, Overexpression of Grb2/HER2 signaling in Chinese gastric cancer: their relationship with clinicopathological parameters and prognostic significance, J Cancer Res Clin Oncol, 2009, 135(10):1331-1339.
24. Marx AH, Tharun L, Muth J, Dancau AM, Simon R, Yekebas E, Kaifi JT, Mirlacher M, Brümmendorf TH, Bokemeyer C, Izbicki JR, Sauter G, HER-2 amplification is highly homogenous in gastric cancer, Hum Pathol, 2009, 40(6):769-777.
25. Moelans CB, Milne AN, Morsink FH, Offerhaus GJA, van Diest PJ, Low frequency of HER2 amplification and over-expression in early onset gastric cancer, Cell Oncol (Dordr), 2011, 34(2):89-95.
26. Beltran Gárate B, Yabar Berrocal A, HER2 expression in gastric cancer in Peru, Rev Gastroenterol Peru, 2010, 30(4):324-327.
27. Cidon EU, Centeno RG, Lagarto EG, Peral JI, HER-2 evaluation in a specific gastric cancer population with the highest rate of mortality in Spain, J Oncol, 2011, 2011: 391564.
28. Lemoine NR, Jain S, Silvestre F, Lopes C, Hughes CM, McLelland E, Gullick WJ, Filipe MI, Amplification and overexpression of the EGF receptor and c-erbB-2 proto-oncogenes in human stomach cancer, Br J Cancer, 1991, 64(1):79-83.
29. Matsui Y, Inomata M, Tojigamori M, Sonoda K, Shiraishi N, Kitano S, Suppression of tumor growth in human gastric cancer with HER2 overexpression by an anti-HER2 antibody in a murine model, Int J Oncol, 2005, 27(3):681-685.
30. Gong SJ, Jin CJ, Rha SY, Chung HC, Growth inhibitory effects of trastuzumab and chemotherapeutic drugs in gastric cancer cell lines, Cancer Lett, 2004, 214(2):215-224.
31. Kim SY, Kim HP, Kim YJ, Oh do Y, Im SA, Lee D, Jong HS, Kim TY, Bang YJ, Trastuzumab inhibits the growth of human gastric cancer cell lines with HER2 amplification synergistically with cisplatin, Int J Oncol, 2008, 32(1):89-95.
32. Grávalos C, Gómez-Martín C, Rivera F, Alés I, Queralt B, Márquez A, Jiménez U, Alonso V, García-Carbonero R, Sastre J, Colomer R, Cortés-Funes H, Jimeno A, Phase II study of trastuzumab and cisplatin as first-line therapy in patients with HER2-positive advanced gastric or gastro-esophageal junction cancer, Clin Transl Oncol, 2011, 13(3): 179-184.
33. Ross JS, Mulcahy M, HER2 testing in gastric/gastro-esophageal junction adenocarcinomas: unique features of a familiar test, Gastrointest Cancer Res, 2011, 4(2):62-66.
34. Inui T, Asakawa A, Morita Y, Mizuno S, Natori T, Kawaguchi A, Murakami M, Hishikawa Y, Inui A, HER-2 overexpression and targeted treatment by trastuzumab in a very old patient with gastric cancer, J Intern Med, 2006, 260(5):484-487.
35. Rebischung C, Barnoud R, Stéfani L, Faucheron JL, Mousseau M, The effectiveness of trastuzumab (Herceptin) combined with chemotherapy for gastric carcinoma with overexpression of the c-erbB-2 protein, Gastric Cancer, 2005, 8(4):249-252.
36. Folkman J, What is the evidence that tumors are angio-genesis dependent? J Natl Cancer Inst, 1990, 82(1):4-6.
37. Dvorak HF, Sioussat TM, Brown LF, Berse B, Nagy JA, Sotrel A, Manseau EJ, Van de Water L, Senger DR, Distribution of vascular permeability factor (vascular endo-thelial growth factor) in tumors: concentration in tumor blood vessels, J Exp Med, 1991, 174(5):1275-1278.
38. Lazǎr D, Tǎban S, Raica M, Sporea I, Cornianu M, Goldiş A, Vernic C, Immunohistochemical evaluation of the tumor neoangiogenesis as a prognostic factor for gastric cancers, Rom J Morphol Embryol, 2008, 49(2):137-148.
39. Joo YE, Sohn YH, Joo SY, Lee WS, Min SW, Park CH, Rew JS, Choi SK, Park CS, Kim YJ, Kim SJ, The role of vascular endothelial growth factor (VEGF) and p53 status for angiogenesis in gastric cancer, Korean J Intern Med, 2002, 17(4):211-219.
40. Iordache S, Saftoiu A, Georgescu CV, Ramboiu S, Gheonea DI, Filip M, Schenker M, Ciurea T, Vascular endothelial growth factor expression and microvessel density - two useful tools for the assessment of prognosis and survival in gastric cancer patients, J Gastrointestin Liver Dis, 2010, 19(2):135-139.
41. Yang Q, Ye ZY, Zhang JX, Tao HQ, Li SG, Zhao ZS, Expression of matrix metalloproteinase-9 mRNA and vascular endothelial growth factor protein in gastric carcinoma and its relationship to its pathological features and prognosis, Anat Rec (Hoboken), 2010, 293(12):2012-2019.
42. Du JR, Jiang Y, Zhang YM, Fu H, Vascular endothelial growth factor and microvascular density in esophageal and gastric carcinomas, World J Gastroenterol, 2003, 9(7):1604-1606.
43. Li SG, Ye ZY, Zhao ZS, Tao HQ, Wang YY, Niu CY, Correlation of integrin beta3 mRNA and vascular endothelial growth factor protein expression profiles with the clinicopathological features and prognosis of gastric carcinoma, World J Gastroenterol, 2008, 14(3):421-427.
44. Karayiannakis AJ, Syrigos KN, Polychronidis A, Zbar A, Kouraklis G, Simopoulos C, Karatzas G, Circulating VEGF levels in the serum of gastric cancer patients: correlation with pathological variables, patient survival, and tumor surgery, Ann Surg, 2002, 236(1):37-42.
45. Ding S, Lin S, Dong X, Yang X, Qu H, Huang S, Liu W, Zhou L, Liu D, Potential prognostic value of circulating levels of vascular endothelial growth factor-A in patients with gastric cancer, In Vivo, 2005, 19(4):793-795.
46. Zhou YJ, Xiong YX, Wu XT, Shi D, Fan W, Zhou T, Li YC, Huang X, Inactivation of PTEN is associated with increased angiogenesis and VEGF overexpression in gastric cancer, World J Gastroenterol, 2004, 10(21):3225-3229.
47. Tenderenda M, Rutkowski P, Jesionek-Kupnicka D, Kubiak R, Expression of CD34 in gastric cancer and its correlation with histology, stage, proliferation activity, p53 expression and apoptotic index, Pathol Oncol Res, 2001, 7(2):129-134.
48. Takahashi Y, Cleary KR, Mai M, Kitadai Y, Bucana CD, Ellis LM, Significance of vessel count and vascular endothelial growth factor and its receptor (KDR) in intestinal-type gastric cancer, Clin Cancer Res, 1996, 2(10): 1679-1684.